MDT

89.82

+1.17%↑

VEEV

281.68

+0.62%↑

A

114.48

-0.44%↓

WBA

11.5

-0.17%↓

HQY

98.08

-0.93%↓

MDT

89.82

+1.17%↑

VEEV

281.68

+0.62%↑

A

114.48

-0.44%↓

WBA

11.5

-0.17%↓

HQY

98.08

-0.93%↓

MDT

89.82

+1.17%↑

VEEV

281.68

+0.62%↑

A

114.48

-0.44%↓

WBA

11.5

-0.17%↓

HQY

98.08

-0.93%↓

MDT

89.82

+1.17%↑

VEEV

281.68

+0.62%↑

A

114.48

-0.44%↓

WBA

11.5

-0.17%↓

HQY

98.08

-0.93%↓

MDT

89.82

+1.17%↑

VEEV

281.68

+0.62%↑

A

114.48

-0.44%↓

WBA

11.5

-0.17%↓

HQY

98.08

-0.93%↓

Search

Ovid therapeutics Inc

Deschisă

SectorSănătate

0.52 10.64

Rezumat

Modificarea prețului

24h

Curent

Minim

0.43

Maxim

0.52

Indicatori cheie

By Trading Economics

Venit

-982K

-10M

Vânzări

54K

130K

Marjă de profit

-7,873.077

Angajați

23

EBITDA

-1.8M

-12M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+489.58% upside

Dividende

By Dow Jones

Următoarele câștiguri

12 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

3.3M

28M

Deschiderea anterioară

-10.12

Închiderea anterioară

0.52

Sentimentul știrilor

By Acuity

50%

50%

169 / 376 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Ovid therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

17 iul. 2025, 23:34 UTC

Achiziții, Fuziuni, Preluări

FTC Reopens Consent Orders for Proposed Acquisitions from Exxon Mobil, Chevron

17 iul. 2025, 21:14 UTC

Achiziții, Fuziuni, Preluări

Basel Medical Group Puts $1 Billion Bitcoin Purchase on Hold

17 iul. 2025, 21:04 UTC

Principalele dinamici ale pieței
Achiziții, Fuziuni, Preluări

Norfolk Southern Shares Rise on WSJ Report of Union Pacific Acquisition Interest

17 iul. 2025, 23:43 UTC

Market Talk

Gold Edges Higher on Possible Position Adjustments -- Market Talk

17 iul. 2025, 23:42 UTC

Market Talk

Nikkei May Rise on Signs of U.S. Econ Strength -- Market Talk

17 iul. 2025, 22:47 UTC

Achiziții, Fuziuni, Preluări

FTC: Maintaining Restrictions for Former Pioneer CEO Scott Sheffield Would Damage FTC's Credibility

17 iul. 2025, 22:46 UTC

Achiziții, Fuziuni, Preluări

Potential Rail Merger Could Prompt Berkshire Hathaway to Bid for CSX -- Barrons.com

17 iul. 2025, 22:46 UTC

Achiziții, Fuziuni, Preluări

FTC Also Says Exxon Order Disregarded Guidelines and Precedent

17 iul. 2025, 22:43 UTC

Achiziții, Fuziuni, Preluări

FTC: Maintaining Restrictions on John Hess's Employment Would 'Damage the FTC's Credibility'

17 iul. 2025, 22:43 UTC

Achiziții, Fuziuni, Preluări

FTC: Chevron Order Disregarded FTC Merger Guidelines and Decades of Precedent

17 iul. 2025, 22:40 UTC

Achiziții, Fuziuni, Preluări

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 iul. 2025, 22:40 UTC

Achiziții, Fuziuni, Preluări

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 iul. 2025, 22:30 UTC

Market Talk
Câștiguri

Netflix Sticks to Its Playbook as Competitive Landscape Changes -- Market Talk

17 iul. 2025, 22:20 UTC

Market Talk
Câștiguri

Global Equities Roundup: Market Talk

17 iul. 2025, 22:20 UTC

Market Talk
Câștiguri

Netflix Focusing Resources on TV Viewers It Hasn't Yet Captured -- Market Talk

17 iul. 2025, 22:04 UTC

Market Talk
Câștiguri

Netflix Redesign Done to Match Current Capabilities -- Market Talk

17 iul. 2025, 22:03 UTC

Achiziții, Fuziuni, Preluări

China Threatens to Block Panama Ports Deal Unless Its Shipping Giant Is Part of It -- 2nd Update

17 iul. 2025, 21:58 UTC

Market Talk
Câștiguri

Netflix Internal Data Doesn't Indicate Weaker Consumer Sentiment -- Market Talk

17 iul. 2025, 21:57 UTC

Câștiguri

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 iul. 2025, 21:47 UTC

Câștiguri

Netflix Raises Revenue, Margin Forecasts After Strong Second Quarter -- Update

17 iul. 2025, 21:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 iul. 2025, 21:45 UTC

Market Talk

Crypto Bills Welcomed by Venture Capital, Trade Group Says -- Market Talk

17 iul. 2025, 21:38 UTC

Achiziții, Fuziuni, Preluări

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- 2nd Update

17 iul. 2025, 21:22 UTC

Achiziții, Fuziuni, Preluări

Update: Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 iul. 2025, 21:05 UTC

Câștiguri

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 iul. 2025, 21:04 UTC

Achiziții, Fuziuni, Preluări

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- Update

17 iul. 2025, 21:02 UTC

Achiziții, Fuziuni, Preluări

Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 iul. 2025, 20:59 UTC

Achiziții, Fuziuni, Preluări

Basel Medical Group Puts $1B Bitcoin Purchase on Hold

17 iul. 2025, 20:50 UTC

Market Talk
Câștiguri

Tech, Media & Telecom Roundup: Market Talk

17 iul. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

Comparație

Modificare preț

Ovid therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

489.58% sus

Prognoză pe 12 luni

Medie 2.83 USD  489.58%

Maxim 4 USD

Minim 1.5 USD

În baza a 5 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruOvid therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

5 ratings

5

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

0.275 / 0.33Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Bullish Evidence

Termen lung

Weak Bearish Evidence

Sentiment

By Acuity

169 / 376 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.